Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | JAVELIN Bladder 100: duration of treatment-free interval

Srikala S. Sridhar, MD, MSc, FRCPC, Princess Margaret Hospital, Toronto, Canada, summarizes findings from the Phase 3 JAVELIN Bladder 100 trial (NCT02603432) in selected subgroups, which assessed avelumab in patients with advanced urothelial carcinoma (UC). Patients received avelumab as maintenance therapy in addition to first-line chemotherapy therapy and overall survival (OS) was improved in patients receiving avelumab regardless of the duration of the treatment-free interval. The benefits of having a treatment-free interval between chemotherapy and immunotherapy are additionally shown in the results of the KEYNOTE-361 (NCT02853305) and IMvigor130 (NCT02807636) trials. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.


Srikala S. Sridhar, MD, MSc, FRCPC has received consultancy/advisory fees from Merck, Pfizer, Roche, BMS, Bayer, Astra Zeneca, Astellas, Janssen, Seattle Genetics, and Immunomedex.